Abstract Library

#648 Mammalian Target of Rapamycin (mTOR) Expression Analysis and Therapeutic Approach in Primitive (T) and Metastatic (M) Ileal Neuroendocrine Tumors (INT)

Introduction: mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine pancreatic carcinoma therapy. Because of varying behavior, INT are usually excluded from clinical trials employing the mTOR inhibitor, RAD001.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: MILIONE M

Authors: Milione M, Pusceddu S, Buzzoni R, Damato A, Coppa J,

Keywords: mTor, midgut, carcinoid,

#116 Transarterial chemoembolization (TACE) of liver metastasis from pancreatic well-differentiated endocrine carcinoma

Introduction: The behavior of liver metastasis from endocrine pancreatic carcinoma is eterogeneous, and several treatments have been proposed, but no single option is ideal.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Zerbi A

Authors: Capitanio V, Papa M, Zerbi A, Vitali G, De Cobelli F,

Keywords: endocrine tumor, liver metastasis, chemoembolization,

#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma

Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Kaemmerer D, Vikas P, Daffner W, Hörsch D, Klöppel G,

Keywords: endocrine pancreatic carcinoma, peptide receptor radionuclide therapy, neodjuvant treatment, pancreatic surgery, molecular imaging, receptor PET/CT,